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Abstract
Background. The incidence and clinical features of the malignant transformation of benign meningiomas are 
poorly understood. This study examined the risk of the malignant transformation of benign meningiomas after 
surgery or stereotactic radiosurgery.
Methods. We systematically reviewed studies published between 1979 and 2019 using PubMed, Scopus, and other 
sources. We analyzed pooled data according to the PRISMA guideline to clarify the incidence rate of malignant 
transformation (IMT) and factors affecting malignant transformation in surgically or radiosurgically treated benign 
meningiomas.
Results. IMT was 2.98/1000 patient-years (95% confidence interval [CI]  =  1.9–4.3) in 13 studies in a single-arm 
meta-analysis. Although the evidence level of the included studies was low, the heterogeneity of the incidence was 
mostly explained by the tumor location. In meta-regression analysis, skull base tumors had a significantly lower 
IMT than non-skull base tumors, but no gender association was observed. IMT after radiosurgery in 9 studies was 
0.50/1000 person-years (95% CI = 0.02–1.38). However, a higher proportion of skull base tumors, lower proportion 
of males, and lower salvage surgery rate were observed in the radiosurgery group than in the surgery group. The 
median time to malignant change was 5 years (interquartile range = 2.5–8.2), and the median survival after malig-
nant transformation was 4.7 years (95% CI = 3.7–8) in individual case data.
Conclusion. IMT of benign meningioma was significantly affected by the tumor location. Radiosurgery did not ap-
pear to increase IMT, but exact comparisons were difficult because of differences in study populations.
Key Points
 • IMT after surgery for benign meningioma was 2.98/1000 person-years.
 • A skull base tumor location strongly affected IMT.
 • IMT after radiosurgery was influenced by its specific patient background.
Meningiomas are usually indolent tumors that often remain 
asymptomatic.1 Even when symptomatic, approximately 80% 
of meningiomas are categorized as WHO grade I  and slow-
growing tumors that exhibit decelerated growth during enlarge-
ment.2 However, even benign meningiomas can recur after total 
removal, and some of these lesions are known to behave more 
malignantly. The prognostic factors of benign meningiomas have 
been investigated by several authors. The extent of removal is the 
most important factor,3–5 and tumor proliferative potential, tumor 
location, and gender are probable candidates.6–9
Malignant transformation of WHO grade I meningiomas 
after surgery or radiosurgery: systematic review and 
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Atypical or anaplastic meningiomas are likely to recur, 
and they are associated with poor clinical courses. High-
grade meningiomas have significantly elevated rates of 
chromosomal gains and losses, especially among tumors 
with monosomy 22,10 and they carry a higher mutation 
burden than low-grade tumors. DNA methylation patterns 
may serve as diagnostic biomarkers for malignancy.11 It is 
reported that approximately 20–40% of meningiomas are 
secondary tumors that originated from WHO grade I  tu-
mors.12–14 Reports in the literature indicate stepwise ge-
netic progression, with the deletion of chromosome 22 
representing the fundamental alteration and deletions in 
other chromosomes (1p, 14q, and 10q) occurring during 
the progression of these tumors toward a more malignant 
type.15–17 Consequently, higher-grade meningiomas are 
categorized as de novo or secondary tumors.18 There may 
be genetic differences between these 2 types; specifically, 
promoter mutation of hTERT is sometimes found in the 
latter but rarely detected in the former.18–20 However, the 
differences between de novo and secondary higher-grade 
meningiomas are unclear.
It has been reported that 1–2% of benign meningiomas 
transform into higher-grade lesions, but these data were 
based on the old pathological grading system prior to 
the release of WHO 2000.21,22 Schiffer et al.23 claimed that 
malignant transformation was extremely rare, observing 
transformation to an atypical lesion in only 2 of 53 cases of 
recurrence of initially benign meningioma according to the 
WHO 2000 criteria. Conversely, McGovern et al.24 reported 
that 8 tumors progressed to atypical or anaplastic lesions 
during recurrence among 175 benign tumors based on 
the WHO 2000 criteria. Yeon et al.25 and Champeaux et al.4 
reported that 2.7% and 2.2% of benign meningiomas ex-
hibited malignant progression based on the WHO 2016 cri-
teria, respectively. It is unclear whether these differences 
are based on the differences of the pathological criteria 
or other factors such as changes in treatment modalities 
and the increased use of radiosurgery. For rare outcomes, 
meta-analysis may be the only method for obtaining reli-
able evidence.
Stereotactic radiosurgery (SR) is a treatment option 
for patients with recurrent or surgically challenging re-
sidual tumors. A  major concern of SR is the expected 
risk of new malignancy or malignant transformation. 
Fractionated radiotherapy is well known to be related to 
oncogenesis.26 Meningiomas previously treated with ad-
juvant radiation exhibit a significantly higher frequency 
of copy number alterations than radiation-induced 
or radiation-naïve meningiomas.10 However, a recent 
multicenter cohort study reported no malignant trans-
formation among 1490 benign meningiomas treated 
with SR during a median follow-up period of 8.1 years.27 
Conversely, other studies reported a relatively higher 
transformation rate in meningiomas treated with 
SR.28,29 The effect of SR on malignant transformation in 
meningiomas is thus uncertain.
Because of its rarity, the incidence and clinical features 
of the malignant transformation of benign meningiomas 
are poorly understood. We systematically reviewed pre-
viously reported cases of initially benign meningiomas 
that displayed malignant transformation. We estimated 
the incidence rate of malignant transformation (IMT) be-
cause the percentage of malignant transformation (PMT) 
may increase with longer follow-up. We examined whether 
known prognostic factors of benign meningiomas (extent 
of removal, location, and gender) were associated with 
malignant transformation. Individual case data were ana-
lyzed to identify the clinical features of this aggressive 
tumor. Another aim of this study was to compare the fre-
quency of malignant transformation between surgical and 
radiosurgical series.
Materials and Methods
Literature Search and Data Extraction
This study followed the PRISMA statement 
(Supplementary File 1). The search flow diagram is out-
lined in Supplementary Figure 1. We used the key-
words “meningioma” and “recurrence” combined with 
“human” to search for studies published in English or 
Japanese from 1979 to December 2019 in PubMed, Scopus, 
Cochrane Library, and Google Scholar. In addition, we 
searched in Japan Medical Abstract Society. “Malignant 
transformation,” “malignant change,” “malignant pro-
gression,” and dedifferentiation were the combined key-
words. Studies confined to neurofibromatosis, pediatric 
studies, and studies of restricted tumor locations were 
excluded. Studies of spinal, optic nerve, and intraorbital 
meningiomas were also excluded. Two of the authors 
searched the literature independently, and the final selec-
tion was performed via discussion.
Because the majority of the selected studies reported 
outcomes for patients without focusing on “malignant 
Importance of the Study
Some benign meningiomas recur as higher-
grade lesions. Although their prognosis is re-
portedly worse than that of de novo high-grade 
meningiomas, the incidence and clinical fea-
tures of such aggressive grade I meningiomas 
are unknown. We conducted a meta-analysis 
and systematic review and found that the 
incidence rate was 2.98/1000 person-years. The 
rate was influenced by the tumor location. The 
low rate after radiosurgery (0.5/1000 person-
years) is probably attributable to the high pro-
portion of skull base tumors and low rate of 
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transformation,” they often lacked necessary data. We at-
tempted to obtain the data by contacting the authors of 
each study. Four of the authors kindly responded to our 
e-mails, and 3 authors provided the necessary data.5,25,30
Risk of Bias
As all analyses were retrospective observational studies 
that described the rate of malignant transformation for be-
nign meningiomas, we did not use a specific method to 
assess the risk of bias. Instead, we carefully investigated 
the heterogeneity of the studies. Publication bias was as-
sessed in analyses including more than 10 studies.
One possible bias was that each surgical study em-
ployed different WHO pathological criteria. Meanwhile, the 
initial diagnosis was not available for a median of 40.8% 
(interquartile range [IQR] = 33.0–46.8) of patients in the SR 
group. We evaluated these factors in statistical analysis.
Extraction of Incidence Data
We included studies that described at least 50 cases of WHO 
grade I meningioma with suitable follow-up periods and the 
rate of malignant transformation at the time of recurrence. 
IMT was calculated as the number of transformations per 
1000 person-years. Separately, PMT was calculated in 
studies with a mean follow-up period exceeding 5 years. 
In each study, PMT was defined as the number of observa-
tions of malignant transformation divided by the number 
of all observations. As PMT did not account for the obser-
vational time, this variable was difficult to interpret statis-
tically. However, if the rate of malignant transformation of 
meningioma plateaus during a long observation time, PMT 
is a more appropriate outcome than IMT.
When only the median follow-up data were available, 
means were calculated using the following equation 
obtained from 11 studies that described both mean and 
median values (R2 = 0.95): mean = 1.13 × median.
In each study, we collected the median or mean age at 
initial presentation and follow-up period, sex distribution, 
and the numbers of WHO grade I  benign meningiomas, 
recurrences, and malignant transformations. The tumor 
location was categorized as a skull base (SB) and a non-
skull base (NSB). When the exact data for tumor location or 
gender were available for all-grade meningiomas but not 
for grade I exclusively, the former data were used to esti-
mate the rate of SB tumors and the proportion of males. 
We also assessed the rate of surgical treatment before SR 
and at the time of recurrence or progression.
Extraction of Individual Case Data
We selected the data of individual cases of benign 
meningiomas with a malignant transformation from arti-
cles identified during the literature search. The selected 
articles included both research and case reports. In this 
analysis, we extracted individual data for initial age, sex, 
tumor location, time to malignant change, number of re-
currences before the malignant change, receipt of radiation 
therapy before and after malignant transformation, sur-
vival after malignant transformation (SMT), initial histolog-
ical findings, and initial radiological findings on CT or MRI 
when available. We collected data regarding the existence 
of perifocal edema, tumor shape (lobulated or round), and 
homogeneity after contrast enhancement as radiological 
findings and the subtype of meningiomas and existence of 
mitoses as histological findings.
Pathological Diagnosis
The WHO grading system for brain tumors was first published 
in 1979,31 and the criteria have been revised several times. 
Because the initial WHO grading system of meningiomas 
included hemangiopericytic and hemangioblastic types, we 
excluded them from the analyses. The distinction of atypical 
meningiomas was not described until the WHO 1993 grading 
system,32 whereas many studies distinguished this aggres-
sive subtype after the publication of studies by Jellinger 
et  al.21 and Jääskeläinen et  al.22 Meningioma grading cri-
teria were substantially revised in 2000.33 At this time, 
brain-invasive but otherwise benign meningiomas were 
not categorized as atypical meningiomas, but they were 
described as aggressive tumors with the same biological 
activity as atypical meningiomas. The 2007 classification de-
fined that brain-invasive but otherwise benign meningiomas 
should prognostically be considered WHO grade II lesions,34 
but the WHO 2016 criteria classified these tumors as atypical 
lesions.35 In statistical analyses, we categorized the WHO cri-
teria into 3 groups: before 2000, 2000 and 2007, and 2016. 
When a study using the WHO 2007 criteria classified brain-
invasive meningiomas as atypical tumors, it was included to 
the WHO 2016 group.
In individual case analyses, several case reports or series 
published before the WHO 2016 classification categorized 
brain-invasive meningiomas as non-benign tumors. If it 
was not the case, then we categorized them as atypical 
meningiomas whenever possible. Some old studies re-
porting individual case data described precise histological 
findings about cellularity, loss of architecture, mitosis, ne-
crosis, and brain invasion. We reclassified such tumors ac-
cording to the WHO 2016 classification.35
Statistical Analysis
We used R statistical software for statistical analyses. 
Because the selected studies that covered a long period 
were expected to report heterogeneous data, the 
random-effects model was applied in the meta-analysis 
(DerSimonian–Laird method). We used “metarate” in R to 
perform a single-arm meta-analysis to calculate IMT or 
PMT. Because several studies reported a null incidence, 
we applied the Freeman–Tukey double arcsine method 
for transformation. Publication bias was estimated using 
a funnel plot when 10 or more studies were included. 
Linear regression analysis was used in the test for funnel 
plot asymmetry. The reviewed studies were tested for 
heterogeneity (Q test, I2 statistic), and we performed 
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For individual data analyses, univariate analysis was 
conducted via the Fisher’s exact test for categorical vari-
ables and the Mann–Whitney U test or Kruskal–Wallis test 
for continuous variables using EZR in R.36 Possible candi-
date predictors related to survival were included in mul-
tivariate regression analysis performed using the Wald 
method. The Kaplan–Meier method was used in survival 
analyses. We performed analyses using the log-rank test 
and Cox proportional hazard test. The correlations of 2 fac-
tors were examined using Pearson’s correlation coefficient 
(r).
Two-sided P < .05 was considered statistically significant.
Ethical Approval and Informed Consent
This review did not involve direct studies on humans, and 
thus, informed consent not was required.
Results
In the postsurgical series, we selected 13 studies with fol-
low-up data for incidence analysis4,5,24,25,30,37–44 and an-
other 2 studies with follow-up periods exceeding 5 years 
but unknown mean values for percentage analysis22,45 
(Supplementary Table 1).
In the SR series of meningiomas, we identified 13 
studies.27–29,46–55 Two large multicenter studies covered 
the results of some of these studies.27,29 Because the 2 
multicenter studies contained data from overlapping insti-
tutes, we chose a larger study with necessary data for data 
extraction. Finally, we selected 9 studies for incidence ana-
lyses to avoid overlapping data28,29,47,50–57 (Supplementary 
Table 2).
We selected 172 cases from 93 articles for individual 
case data analysis (Supplementary Table 3). Sixty-five 
cases were obtained from case reports, and 107 cases were 
obtained from research articles.
Malignant Transformation in Surgical Series
Thirteen postsurgical series reported 56 cases of malig-
nant transformation among 2639 patients with WHO grade 
I meningiomas during a median follow-up period of 6 years 
(IQR  =  5.7–8.1, Table  1).4,5,24,25,30,37–44 IMT was 2.98/1000 
patient-years (95% confidence interval [CI]  = 1.9–4.3, test 
of heterogeneity: Q [df = 12] = 19.46, P = .078, Figure 1A). 
The funnel plot exhibited slight asymmetry without signifi-
cance (P = .063) in a linear regression test.
PMT was determined from studies with a mean follow-up 
period exceeding 5 years. We excluded 1 study with a short 
follow-up period and included 2 other studies that had ap-
parently follow-up periods exceeding 5 years without spe-
cifying the exact duration.22,45 According to data from the 
14 studies, PMT was 2.16% (95% CI = 1.46–2.96).
When transformation numbers were plotted against 
person-years in each study, a significant correlation was 
found (R2 = 0.41, P = .02, Figure 2A) despite the use of dif-
ferent WHO grading systems. Studies with a high SB tumor 
rate (>50%) reported a low transformation rate (Figure 2A). 
If 3 studies with an SB tumor rate exceeding 50% were ex-
cluded, the correlation became much stronger (R2 = 0.77, 
P = .0009).
Factors Related to Malignant Transformation
We analyzed contributing factors to IMT via meta-
regression. IMT did not differ by WHO grading system 
(test for residual heterogeneity: Q [df = 2] = 0.728, P = .695, 
Figure 2B).
Meta-regression analysis revealed that an SB tumor loca-
tion significantly affected IMT (Q [df = 10] = 5.889, P = .0005, 
  
Table 1. Study Population in Surgery and Radiosurgery Group
Surgery Group Radiosurgery Group
2639 Patients in 13 Studies 5969 Patients in 9 Studies
Total Median Total Median
Gender, Female/male 1050/410 (n = 9) Male rate 27.5%, IQR 
[26.3–29.7]
1580/502 (n = 7) Male rate 25.4%, IQR 
[20.5–30.5]
Age (years) n = 12 54.7, IQR [51.7–58.1] n = 8 55.7, IQR [54.1–57.1]
Skull base/non-skull base 625/759 (n = 9) SB rate 41.5%, IQR [38.3–
49.4]
1027/325 (n = 5) SB rate 73.7%, IQR 
[69.8–77.5]
Recurrence or progression 468/2639 (n = 13) 18.8%, IQR [9.2–26.4] 464/5969 (n = 7) 7.5%, IQR [5.4–9.2]
Follow-up period (years) n = 13 6.0, IQR [5.7–8.1] n = 9 5.7, IQR [3.5–7.1]
Salvage surgery for recur-
rence
196/388 (n = 9) Rate* 68.4%, IQR [33.3–89.4] 94/455 (n = 8) Rate* 35.9%, IQR [26.2–43.3]
Malignant transformation 56 in 2639 (n = 13) PMT 2.16% (n = 14) 24 in 5969 (n = 9) PMT 0.51% (n = 6)
Transformation per 
person-year
56 in 17 683 
(n = 13)
IMT 2.98/1000 person-year 24 in 34 589 
(n = 9)
IMT 0.50/1000 person-year
Total, the total number in the studies; median, the median value in the studies; male rate, male number/total number; SB rate, number of skull base 
tumor/total number; Rate*, number of salvage surgery/number of recurrence or progression; PMT, percentage of malignant transformation; IMT, 
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Figure 3A), whereas the relationship between gender and 
IMT did not reach significance (P = .088, Figure 3B).
The relationship between the extent of initial surgical 
resection and the frequency of malignant transformation 
was available in only 3 studies.24,39,42 We were unable to 
evaluate the relationship because these studies lacked 
time-scale data, whereas meta-analysis of odds ratios 
(ORs) did not reveal a significant effect (P = .21).
Malignant Transformation After SR
Nine studies including one large multicenter retrospec-
tive studies reported 24 cases of malignant transformation 
among 5969 patients (Table  1).28,29,47,50–55 Of these, 3062 
(51.2%) patients underwent surgery before SR, whereas 
a pathological diagnosis was not available for the other 
patients. When transformation numbers in each study 
were plotted against person-years, the correlation was 
poor (R2 = 0.30, P = .16). The incidence was approximately 
0.50/1000 person-years (95% CI = 0.02–1.38, Figure 1B).
Remarkably, SR studies displayed high heterogeneity 
concerning IMT (I2 = 63%). We performed a meta-regression 
analysis of location, gender, and the rate of salvage sur-
gery after progression (salvage surgery/total treated pa-
tients). However, we could not identify the cause. Only the 
rate of salvage surgery displayed borderline significance 
(P = .079). We were unable to compare the difference by the 
WHO grading system because of the lack of data.
PMT was determined from 6 studies with mean follow-up 
periods exceeding 5 years as 0.51% (95% CI = 0.18–1.41, 
Table  1). Although both IMT and PMT were much lower 
in the SR group than in the surgery group, the features of 
the populations were completely different between these 
groups (Table 1). Patients in the SR group had a higher rate 
of SB tumors, a higher proportion of female patients, and a 
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Heterogeneity: I2 = 63%, τ2 = .0002, p < .01







/noa/article/2/1/vdaa129/5925038 by guest on 11 D
ecem
ber 2020
 6 Nakasu et al. Malignant transformation of benign meningiomas
According to imaging, 40–70% of lesions in the SR 
series were presumably benign meningiomas. Because 
the majority of studies presented no cases of “malignant 
transformation without initial surgery,” such cases might 
have been excluded from the studies. Therefore, we sep-
arately analyzed patients who underwent surgery before 
radiosurgery. IMT in this group was 0.82/1000 patient-
years (95% CI = 0.0–3.02). The rate of malignant transforma-
tion was determined from 6 studies with a mean follow-up 
period exceeding 5 years as 1.11% (95% CI = 0.00–3.58).
Individual Case Analyses
One hundred seventy-two cases were analyzed 
(Supplementary Table 3), including 92 females and 80 males 
(Table 2). The median age at initial diagnosis was 52 years. 
The majority of meningiomas transformed at the first 
(62%) or second recurrence (27.2%), whereas transforma-
tion after the third recurrence was less common. SB tumors 
(n = 41) were far less common than NSB tumors (n = 104). 
Transformed SB tumors were more frequently observed in 
female patients than in male patients (29 vs 12, P = .038), 
whereas the number of NSB tumors was similar between 
females and males (51 vs 53). Pathological and radiological 
findings were rarely obtained. Meningotheliomatous me-
ningioma was the most frequent subtype at the initial path-
ological diagnosis. Most fibrous (14/15) and transitional 
meningiomas (19/23) were NSB tumors, whereas 35.6% of 
meningotheliomatous meningiomas (21/59) had an SB lo-
cation (P = .04).
No differences were found concerning the initial age at 
diagnosis, sex, location, and extent of resection between 
studies published before and after 2001. However, pa-
tients described in studies published in 2001 or later more 
frequently underwent radiation therapy (including SR) be-
fore malignant transformation (38/99 vs 2/54, P  =  .0001) 
than those described in earlier studies, and they more 
commonly had WHO grade II (61 vs 21, P = .025).
Time to Malignant Transformation
Median time to malignant transformation (TimeMT) was 
5  years (IQR  =  2.5–8.2). Tumors in younger patients had 
a longer TimeMT (r  = −0.33, P  =  .032). In univariate ana-
lyses, TimeMT was significantly longer in patients who re-
ceived radiotherapy before malignant transformation than 
in patients who did not receive radiotherapy (6.6 years vs 
4.0 years, P = .006), whereas no differences were observed 
according to the extent of tumor removal (P  =  .42), sex 
(P = .09), or tumor location (P = .56). Multivariate analyses 
identified younger age as the only factor associated with 
longer TimeMT (P = .004). However, a scatter plot indicated 
that TimeMT was apparently limited by life expectancy in 
elderly patients (>50 years old, Figure 4A).
A primary study aim was to determine IMT. However, no 
reports described the time course of the transformation 
rate. For this purpose, we created a cumulative incidence 
curve of malignant transformation in younger patients 
(≤50 years old, n = 56). The curve revealed an almost linear 
increase in the first 8–9 years and a slower increase there-
after (Figure 4B).
Survival After Malignant Change
SMT was calculated within 30 days after surgery. Overall, 
median SMT was 4.7 years (95% CI = 3–7.8). Factors related 



















































Figure 2. WHO pathological criteria and incidence rate of malignant transformation (IMT). (A) Relationship between the number of malignant 
transformations and person-years (R2 = 0.41, P = .02). Circle, WHO 2016; square, WHO 2000 or 2007; triangle, before WHO 2000. Filled squares or tri-
angles denote studies in which more than 50% of lesions were skull base tumors. (B) IMT did not differ among the WHO grading systems (P = .695). 
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Figure 3. Meta-regression of the incidence rate of malignant transformation (IMT) in surgical series by tumor location (A) and gender (B). A skull 
base location significantly affected IMT (P = .0005), whereas gender had no effect (P = .088). Size of circle = weight.
  
  
Table 2. Individual Case Data: Initial Clinicopathological Features
N = 172
Gender Female 92, Male 80
Initial age (years) Median 52, IQL [41–60] (n = 171)
Mean 50.9, SD 13.4
Time to malignant change (years) Median 5 (n = 154), IQL [2.5–8.2]
Mean 6.6, SD 6.0
Location Non-skull base 104
Convexity 43 Parasagittal 37
Falx 12 Ventricle 5 NA 7
Skull base 41
Frontal base 2 Olfactory groove 3
Cavernous 3 Sphenoid ridge 16
Middle fossa 2 Tentorial 7
CPA 4 Petroclival 2 NA 2
NA 27
Degree of initial resection Total (Simpson 1–3) 86
Subtotal (Simpson 4) 32
NA 54
Initial histology Meningo 61 Fibrous 15 Transit 25
Psamm 1 Secretory 1 NA 69
Mitosis (+) 17 Mitosis (−) 19 NA 136
Initial radiological features Edema (+)16 (−)5
Lobulated shape (+)20 (−)5
Heterogenous CE (+)14 (−)16
Published year After/before 2001, 113/59 (before 1993, 25 cases)
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last WHO grade diagnosis (P =  .003; Table 3). Tumor loca-
tion (P = .63), gender (P = .64), and radiation therapy after 
progression (P = .09) were not prognostic factors. SMT did 
not differ by WHO grading system (P = .38) or type of publi-
cation (case report or research article, P = .09). Multivariate 
analyses illustrated that the WHO grade (grade II [median, 
not reached; 10-year overall survival (OS), 50.1%, 95% 
CI = 23.4–72.0] vs grade III [median, 3.1 years] or grade III 
after grade II [median, 4.1 years]) was the only significant 
prognostic factor (P = .012)
Discussion
In this systematic review and meta-analysis, we calculated 
IMT for benign meningiomas in surgically treated patients 
as 2.98/1000 patient-years. The rate was significantly af-
fected by the tumor location, as SB tumors had a lower 
transformation rate than NSB tumors. The reported inci-
dence in the SR group was much lower than that in the sur-
gery group. However, the surgery and SR groups consisted 
of extremely different patient populations regarding tumor 
location and gender, in addition to differences in patient 
numbers. Therefore, we must cautiously evaluate the role 
of radiosurgery in malignant transformation.
The Rate of Malignant Transformation in the 
Surgery Group
The rate of malignant transformation for benign 
meningiomas has been reported to be as low as 1–2%.21,22 
Recent studies found a wide range of transformation rates 
(0.30–4.9%) for WHO grade I tumors (Supplementary Table 
1). As shown in Figure  4B, malignant transformation oc-
curs more than 20  years after the initial surgery. Thus, 
studies with longer follow-up periods are expected to have 
a higher incidence. For this reason, we evaluated the in-
cidence by person-year and found a relatively good cor-
relation between the number of transformations and the 
duration of follow-up (person-years, Figure 2A). However, 
the cumulative transformation rate in individual data anal-
ysis revealed that malignant transformation may not have 
constantly occurred. Figure 4B illustrates that the increase 
was linear in the first 8–9 years before slowing thereafter. 
The rate of increase may possibly plateau after 30 years. 
The reason for the slower rate is unclear, although it might 
be partly attributable to the loss of patients to follow-up. 
Because of this uncertainty, we do not recommend ap-
plying the incidence rate in this study to predict the risk 
of patients with more than 10  years of follow-up. In this 
context, PMT (2.16%, mean follow-up >5 years) may pos-
sibly increase. Considering median TimeMT in individual 
data analysis to be 5 years (mean, 6.6 years), PMT might 
increase up to 4–5% when sufficient longer follow-up data 
are available.
There was no significant difference in IMT according to 
the pathological criteria (Figure 2B). Although some “be-
nign” tumors in prior WHO grading systems may have 
been considered atypical tumors in new grading systems, 
this appears to be uncommon. Yeon et al.25 revealed that 5 
of 291 meningiomas that were surgically treated between 
1998 and 2013 were reclassified into other grades in the 
WHO 2016 criteria. Our study reported a higher incidence 
of transformation to grade II meningioma in studies re-
ported in 2001 or later than in those reported before 2001 
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Figure 4. (A) Relationship between the initial patient age and time to malignant change in individual case data. Life expectancy curve in 2000 in 
Japan: solid line, women; dotted line, men. (B) Cumulative incidence of malignant transformation in patients ≤50 years old from individual case data. 
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meningiomas (WHO grade III) reported before 2001 might 
have been grade II tumors. Contrarily, in the surgical series, 
we did not detect a difference in IMT among the grading 
systems. Thus, the judgment of histological progression 
to an aggressive form might not be largely affected by 
changes in the pathological criteria.
Tumor Location
Accumulated evidence has revealed differences in 
meningiomas between locations. NSB meningiomas more 
frequently had a high grade than SB tumors.9,56 The differ-
ences may be based on genomic subgroups including NF2 
mutation in NSB tumors, Hedgehog signaling pathway 
mutation in midline tumors, and non-NF2 mutation in an-
terior SB tumors.57 Furthermore, Yoshida et al.58 reported 
that the origin of the meninges differed by location; specif-
ically, the meninges of the midbrain and hindbrain had a 
mesoderm origin, whereas the meninges of the forebrain 
had a neural crest origin.
McGovern et  al.24 first reported a higher malignant 
transformation rate for NSB meningiomas than for SB 
meningiomas using Fisher’s exact test (P = .024). Although 
no other studies compared the malignant transformation 
rate by tumor location, we found that the tumor location 
significantly influenced IMT. In surgical studies, the heter-
ogeneity of IMT was attributable to the proportion of SB 
tumors. The increase in the number of specialized insti-
tutions for SB surgery biased the distribution of the loca-
tion of meningiomas and influenced IMT in each report. 
Conversely, the difference of IMT by tumor location in the 
SR group was not significant because of the uniformly 
high frequency of SB tumors. Although meta-analyses for 
malignant transformation in the SR group indicated that 
an SB location significantly affected the rate of malignant 
transformation (OR = 0.26, 95% CI = 0.08–0.86, P =  .027), 
we were concerned that this analysis did not consider the 
observation period.
Location is a clinically important factor in the treatment 
of meningiomas. SB tumors are generally difficult to treat 
surgically, and consequently, the recurrence rate is high.59 
Interestingly, recent studies revealed biological differences 
between SB and NSB tumors. Hashimoto et al.7 reported 
lower proliferation potential for SB meningiomas, although 
this finding remains controversial. The discrepancy may 
be partly attributable to differences in the classification of 
tumor location. Tentorial meningiomas were previously 
categorized as SB tumors,24 whereas Hashimoto et al.7 and 
others classified them as NSB tumors.59,60 Although we 
categorized these lesions as SB tumors, the rate of malig-
nant transformation for tentorial meningiomas was rela-
tively high in individual case data (Table 2). In fact, recent 
genetic studies demonstrated that tentorial meningiomas 
had a relatively high NF2 mutation rate, similarly as ob-
served for NSB tumors.57
Male sex had borderline significance for high malig-
nant transformation potential in meta-regression analysis. 
Of note, Meling et  al.9 reported that meningiomas more 
frequently have an SB location in females than in males. 
Several other authors reported similar trends without sta-
tistical significance.5,61,62 Therefore, gender differences 
in the rate of transformation might be influenced by the 
tumor location.
TimeMT and Survival in Individual Data
Median TimeMT in individual case data was 5 years (mean, 
6.6 years). The value was comparable with that reported in 
  
Table 3. Survival After Malignant Transformation
Factors Survival Median Years Log Rank Multivariate Cox Proportional Hazard Test 
Gender Female 4.0 (n = 63) P = .64  
Male 4.3 (n = 46)
Age at malignant transformation 55 or less, 6.3 (n = 49) P = .032 P = .10
Older than 55, 3.5 (n = 57)
Last WHO grade Grade II (n = 45) P = .007 II vs III (including III after II)
 NR [4.2–NR]
Grade III (n = 43) P = .012
 3.1 [2.4–4.7]
Grade III after II (n = 21) HR 2.45, 95% CI [1.22–4.93]
 4.1 [1.7–6.3]
Location Skull base 3.0 (n = 25) P = .63  
Non-skull base 4.2 (n = 69)
Radiation after recurrence Yes 4.3 (n = 60) P = .09 P = .09
No 3.0 (n = 25)
Published year 2000 or before 3.7 (n = 46) P = .38  
After 2001 4.6 (n = 63)
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studies that were not included in this analysis. Champeaux 
et al.12 reported in their study of 194 atypical meningiomas 
that 31 benign meningiomas progressed to grade II me-
ningioma after a median of 5.7 years (IQR = 2.1–13). Yang 
et  al.14 analyzed atypical and anaplastic meningiomas, 
observing that 17 of 64 high-grade meningiomas had 
transformed from benign lesions. They found mean 
TimeMT from benign to atypical was 70.0 months, and that 
from benign to anaplastic was 39.8  months. Krayenbühl 
et al.63 reported a mean value of 13.8 years (range. 0.25–24) 
among 10 secondary atypical meningiomas. However, no 
study examined the changes in the rates. Our analysis of 
individual case data revealed a linear increase in the first 
8–9 years with a slower rate thereafter (Figure 4B). Because 
information is limited because the data were compiled 
from case reports or series, further study is necessary for 
reaching a definitive conclusion.
SMT in patients with secondary high-grade meningioma 
is known to be shorter than OS among patients with de 
novo high-grade meningiomas.12,63–65 Mean SMT in pa-
tients with secondary anaplastic meningioma has been 
reported as 1.1–2.1  years.63,64,66 The values were slightly 
smaller than those in our study (median, 3.1 years) because 
the former studies included initially grade II meningiomas. 
In patients with secondary atypical meningioma, the 
present study found that 10-year SMT was 50.1%, com-
parable to that reported by Koh67 (10-year SMT = 49.9%, 
n  =  16). By contrast, Krayenbühl et  al.63 reported mean 
SMT as 1.95 years in 10 patients with secondary atypical 
meningiomas, which was much shorter than our result, 
probably because of the high rate of life-threatening SB tu-
mors (70%) in their study.
Malignant Transformation in the SR Group
This study observed that benign meningiomas were less 
likely to be dedifferentiated after SR. Tumors that were 
treated with SR after surgery, which are generally con-
sidered relatively aggressive,29,50 had lower IMT (0.82/1000 
patient-years) than surgically treated lesions (2.98/1000 
patient-years). However, SR-treated meningiomas were 
more frequently located in the SB than observed in the sur-
gery group. Moreover, SR-treated meningiomas were less 
frequently treated via salvage surgery, resulting in an un-
known histology at progression. Although it is difficult to 
compare the risk of malignant transformation between the 
surgery and SR groups, we found no evidence that SR in-
creased the risk.
Because TimeMT tended to be longer in patients treated 
with radiotherapy than in those treated with surgery alone 
in individual case analysis, longer follow-up is necessary 
to clarify the effects of SR. Additionally, imaging studies 
that can evaluate malignant transformation without sur-
gical intervention would be necessary for a more precise 
estimation of the incidence of malignant transformation.
Limitations
This study had several limitations. All adopted studies 
were retrospective and observational in nature. Although 
we identified several studies that reported surgical or 
radiosurgical outcomes for benign meningiomas, few of 
them reported the number of malignant transformations 
among their cases. The studies rarely described individual 
data for malignant changes. Consequently, the evidence 
level of each study was low. However, the heterogeneity 
of IMT in the surgery group was largely explained by the 
tumor location. Conversely, the heterogeneity of IMT 
in the SR group was not related to the tumor location or 
gender. We speculated that the SR group might have been 
more heterogeneous in the initial selection and treatment 
strategy than the surgery group.
Although Simpson’s grade is considered one of the most 
important factors for prognosis, we were unable to dem-
onstrate an effect of the extent of surgery on the risk of 
malignant transformation in this meta-analysis. This was at-
tributable to the lack of information in most studies. To clarify 
the role of aggressive surgery in the prevention of malignant 
transformation, further accumulation of data is necessary.
We attempted to pool individual data as much as pos-
sible by searching the literature including case reports. The 
pooled cases might have involved more aggressive tu-
mors because case reports tended to report more aggres-
sive cases with metastases or rhabdoid transformation. 
However, we found no differences in gender (P = .21), age 
(P = .46), tumor location (P = .85), time to malignant change 
(P = .34), and survival (P = .09) between data from case re-
ports and research articles.
Conclusion
We found that IMT in benign meningiomas was 2.98/1000 
person-years. However, we caution that the increase of 
malignant transformation may not be constantly linear, 
especially after 10  years. Furthermore, the rate was con-
siderably affected by the location of meningiomas, as SB 
tumors had significantly lower IMT. Although IMT was 
lower in the SR group than in the surgery group, the pa-
tient characteristics of the groups differed. Moreover, IMT 
in the SR group displayed high heterogeneity that was not 
explained by the tumor location or other clinical factors.
Individual case data revealed that median TimeMT was 
5  years, whereas malignant change occurred in patients 
up to 30  years after the initial surgery. In patients with 
secondary atypical meningioma, 10-year OS was 50.1%, 
whereas patients with secondary anaplastic meningioma 
had a median survival of only 3.1 years.
Supplementary Material
Supplementary material is available at Neuro-Oncology 
Advances online.
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